Baseline participant characteristics (n=5662)
| Variable | N (%) |
| Female | 3673 (64.9) |
| Age in years, median (IQR) | 86 (80–90) |
| Age group | |
| <80 | 1276 (22.5) |
| 80–85 | 1494 (26.4) |
| 86–89 | 1258 (22.2) |
| ≥90 | 1634 (28.9) |
| Provider | |
| A | 4269 (75.4) |
| B | 1393 (24.6) |
| Cohort | |
| Entered the facility on or after January 2019 | 3029 (53.5) |
| Entered the facility before January 2019 | 2633 (46.5) |
| Heath status | |
| Any circulatory conditions | 5010 (88.5) |
| Cerebrovascular accident | 1420 (25.1) |
| Any endocrine conditions | 2193 (38.7) |
| Diabetes | 1588 (28.1) |
| Thyroid | 606 (10.7) |
| Chronic respiratory disease | 1043 (18.4) |
| Cancer | 1655 (29.2) |
| Parkinson’s disease | 445 (7.9) |
| Peptic ulcer/gastro-oesophageal reflux disease | 1758 (31.1) |
| Renal disease | 1085 (19.2) |
| Dementia | 2919 (51.6) |
| Osteoporosis | 1627 (28.7) |
| Arthritis | 3239 (57.2) |
| Gout | 561 (9.9) |
| Fracture | 1930 (34.1) |
| Hearing impairment | 1235 (21.8) |
| Depression, mood and affective disorders | 2542 (44.9) |
| Anxiety and stress-related disorders | 1699 (30) |
| Visual impairment | 947 (16.7) |
| Medicines (ATC level 1) | |
| Alimentary tract and metabolism | 2733 (48.3) |
| Anti-infectives for systemic use | 837 (14.8) |
| Antineoplastic and immunomodulating agents | 152 (2.7) |
| Antiparasitic products, insecticides and repellents | 25 (0.4) |
| Blood and blood-forming organs | 1859 (32.8) |
| Cardiovascular system | 2386 (42.1) |
| Dermatologicals | 599 (10.6) |
| Genitourinary system and sex hormones | 456 (8.1) |
| Musculoskeletal system | 612 (10.8) |
| Nervous system | 2461 (43.5) |
| Respiratory system | 634 (11.2) |
| Sensory organs | 810 (14.3) |
| Systemic hormonal preparation | 708 (12.5) |
ATC, Anatomical Therapeutic Classification.